Meroem Injection 0.5g (Meropenem Hydrate)

Adult administration

As Meropenem hydrate, 0.5 to 1 g (activity) should be administered by slow intravenous infusion divided into 2 to 3 doses per day for at least 30 minutes. For suspected infections in patients with pathogenic pneumonia, peritonitis, or neutropenia, 1 g (activity) should be administered by slow intravenous infusion every 8 hours. For cystic fibrosis and meningitis, 2 g (activity) every 8 hours should be administered by slow intravenous infusion.

Child administration

For bacterial meningitis in children over 3 months old, administer a slow intravenous infusion of 40 mg per kg of body weight every 8 hours for 30 minutes, depending on the sensitivity of the pathogen and the patient's condition, as well as the type of infection. Symptoms

This medicine should not be used in patients who have experienced severe allergic reactions or shock to this drug or similar medications in the past. Additionally, patients taking sodium valproate should be cautious as using this medicine together may lower the blood concentration of valproate and could lead to seizures. Individuals with bronchial asthma or allergic predispositions, patients with impaired kidney or liver function, those with a history of epilepsy, infants under 3 months, and elderly patients should be particularly careful when using this medication. Various side effects such as shock, rashes, itching, vomiting, diarrhea, and seizures may occur during the administration of this medicine, so notify medical personnel immediately if any abnormal symptoms arise. Regular blood tests and liver function tests are required because this drug can affect liver and kidney function. This medication may interact with other drugs, especially anticonvulsants, contraceptives, and anticoagulants, so it is important to consult with healthcare professionals and periodically check drug concentrations. Women who are pregnant or could become pregnant should carefully weigh the risks and benefits of administering this medication, and breastfeeding mothers are advised to avoid its use. This medication is administered only by intravenous injection and should be used as soon as possible after reconstitution, and it should also be used within a certain time frame during storage. Lastly, elderly patients are at higher risk for side effects due to declining physiological functions, so dosages and intervals should be adjusted, and careful observation is necessary.

Serious side effects

Shock, anaphylaxis-like reactions, urticaria, severe swelling, chest tightness, difficulty breathing, cold sweat, pallor, severe allergic reactions, severe skin reactions, toxic epidermal necrolysis (Lyell syndrome), Stevens-Johnson syndrome, DRESS syndrome, erythema multiforme, acute generalized exanthematous pustulosis (AGEP), fulminant hepatitis, hepatic failure, jaundice, acute renal failure, severe diarrhea, and membranous colitis.

Mild side effects

• Oral abnormalities
• wheezing
• dizziness
• changes in bowel habits
• tinnitus
• sweating
• heat sensation
• erythema
• itching
• fever

This medicine should be stored in a sealed container to prevent exposure to air, ideally at room temperature between 1 to 30 degrees Celsius. This helps maintain the drug's efficacy and safety.

Appearance

Aster white to light yellow crystalline powder in a colorless and transparent vial for injection.

Package unit

10 vials/box [(604 mg/vial)]